Featured in

• Hess: This Stock Could Leap $12 Higher In 2013

  Hess (HES) has a large variety of oil and gas holdings in the United States and a few strategic locations abroad. With a liquids-rich asset base, Hess is positi...

  
  
• CenturyLink: A Compelling Buy Candidate For 2012

  CenturyLink (CTL) has grown through a series of acquisitions into the third largest US telecommunications company. Wireline connections in 37 states accommodate...

  
  
• CSX: Low Payout Ratio, High Growth Prospects

  Railroad stocks have long been the hallmarks of a good stock portfolio - there is a reason they appear so prominently in Monopoly games - and while fewer people...

  
  
• 5 Oil And Gas Ideas For Your 2012 Portfolio

  Oil and gas companies should play a part in any portfolio. There are numerous companies to choose from, and they cover a wide spectrum of risk tolerance. The co...

  
  
• EMC’s New VSPEX Will Drive Stock Upward

  EMC (EMC) provides hardware, software, and services for enterprise network storage. It has an 80% ownership stake in VMware (VMW). About 75% of EMC's revenue re...

  
  
• Buy This Retail King Now, Skip These 2

  McDonald's (MCD) shares have slipped a bit lately, purportedly on the weaknesses of the eurozone, but given the fact the stock is overvalued some 30% on a disco...

  
  
• Microsoft: A Compelling Candidate Now

  While Apple (AAPL) can't blink without inspiring an absolute riot, savvy investors have not forgotten about the older brother and wiser sage that is Microsoft (...

  
  
• 4 Biotech Stocks With Strong Upside Potential

  The last twelve months have been a rocky ride for Human Genome Sciences (HGSI), once tipped as the bright young things of the Biotechnology industry. Since Apri...

  
  
• Ford, GM: Best Value Plays In A Can’t-Lose Sector

  All signs point to a great year for the auto industry. The economy is improving, interest rates remain low and the last few years for carmakers have been terrib...

  
  
• Competition Will Drive Dendreon’s Stock Down

  A renewed area of focus for many pharmaceutical and biotechnology companies is anti-cancer drugs, but, unlike the past, these drugs target smaller groups of pat...